Hema Now | Episode 10
This week, Jonathan is joined by Fredrik Schjesvold, Head of the Oslo Myeloma Center Oslo University Hospital, Head of the Norwegian myeloma association, and President of the Nordic Myeloma Study Group.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (40 mins)
Fredrik Schjesvold
Fredrik is the founder and head of the Myeloma Center at Oslo University Hospital in Norway, one of Europe’s premier research centres dedicated to the clinical study of multiple myeloma.
With a career focused on advancing treatment for multiple myeloma, Schjesvold is the principal investigator for five academic clinical studies and the national investigator of more than 60 clinical trials in multiple myeloma, in addition to being site investigator in over 10 more. He is head of the Norwegian myeloma association, President of the Nordic Myeloma Study Group and a board member of the European Myeloma Network, and a co-author of European (ESMO) and global (IMWG) guidelines, as well as lead author of the Norwegian myeloma guidelines.
04:24 – Research into melflufen
07:14 – Ide-cel CAR-T cell therapy
09:40 – Predictors of overall survival
12:15 – Innovative therapies for refractory myeloma
14:04 – Bi-specific antibodies
16:42 – Global guidelines for myeloma
22:00 – Healthcare economics
25:45 – Antibody-based therapies
29:38 – Latest research into amyloidosis
34:23 – Recent breakthroughs in myeloma
38:06 – Fredrik’s three wishes for healthcare
